/News/
26 02, 2020

Swiss Rockets AG: Business Advisory Committee will combine business with the patients’ well-being

By |2020-02-25T18:02:32+01:0026th February, 2020|Press Release|

To deliver breakthrough treatments to cancer patients, Swiss Rockets supports innovation through investments in the novel and differentiated ideas and technologies. Swiss Rockets’ business model, promoted by highly competent members of the Business Advisory Committee, will ensure success in transforming cancer care with new and best in class medicines. Dr. Sabina R. Korfmann-Bodenmann, Chairman [...]

10 02, 2020

Prof. Dr. Michael N. Hall, member of the Board of Directors of Swiss Rockets AG, receives the Sjöberg Prize 2020

By |2020-02-10T12:34:33+01:0010th February, 2020|Press Release|

The Royal Swedish Academy of Sciences has awarded the Sjöberg Prize 2020 jointly to Prof. Michael N. Hall, Biozentrum of the University of Basel, and Prof. David M. Sabatini, Massachusetts Institute of Technology (MIT), Cambridge, USA. The two scientists receive this international award for their discovery of mTOR and its role in the control [...]

3 02, 2020

Swiss Rockets AG: The Executive Management Team – People make the Difference

By |2020-02-03T00:15:39+01:003rd February, 2020|Press Release|

Cancer patients of Swiss Rockets AG will benefit from new treatments developed using innovative and disruptive methods. The Swiss Rockets’ executive management team combines the necessary specialist knowledge and experience to efficiently and sustainably break new ground in cancer medicine. Swiss Rockets AG, Basel, founded in 2018, is implementing a paradigm shift in healthcare. [...]

26 11, 2019

Swiss Rockets implements a paradigm shift in the field of cancer research

By |2019-11-26T08:38:54+01:0026th November, 2019|Press Release|

The Swiss Rockets business model will bring advantages first and foremost to cancer patients, but also to researchers of new active substances, and investors. Forward-looking treatment methods within the therapeutic area of oncology will be identified, supported, and commercialized through the combining of services into an incubator for new oncology projects, through targeted investments along [...]